#USA #Cincinnati #Medical Devices #Sense Neuro #Gary Kurdziel

Sense Neuro Diagnostics Welcomes New Leadership

CINCINNATI, March 21, 2025 — In a significant move for the medical device industry, Sense Diagnostics, Inc. has announced the appointment of Gary Kurdziel as its new Chief Executive Officer, effective April 1, 2025. Kurdziel, who previously held the position of Executive Vice President and Chief Commercial Officer at Sense Neuro Diagnostics, brings over three decades of extensive leadership experience in the medical device sector, particularly in the neuroscience field.

As he takes the reins from Geoff Klass, who is retiring following six years of dedicated service, Kurdziel inherits a company poised for substantial growth. His track record at Medtronic, where he served in various Vice President roles across multiple neuroscience businesses, showcases his capability in driving strategic initiatives and achieving remarkable market share increases. Such experience positions him well to elevate Sense Neuro Diagnostics during a time of critical developments, especially as the company prepares to engage with the FDA and the Department of Defense.

In an official statement regarding his new role, Gary Kurdziel expressed his excitement about leading the company. He emphasized Sense Neuro Diagnostics' commitment to transforming care for stroke and traumatic brain injury patients through innovative real-time detection and monitoring technologies.

"I am honored to lead Sense Neuro Diagnostics at this pivotal time as we aim to transform the global standard of care for stroke and traumatic brain injury (TBI)," Kurdziel stated. "By leveraging our innovative technologies, we can empower clinicians to take swift, lifesaving actions that improve patient outcomes and reshape neurological care worldwide."

Under Kurdziel’s leadership, the organization is expected to advance its mission of delivering life-changing solutions to patients. His vision not only includes focusing on the development of new technologies but also on inspiring teams to work collaboratively and efficiently to achieve common goals.

The Board of Directors enthusiastically endorsed the appointment of Kurdziel. Board Chairman Dan Geeding mentioned, "We are delighted to have Gary take over leadership of Sense Neuro Diagnostics as it enters critical phases of work. His extensive experience and dynamic approach will undoubtedly be instrumental in driving our mission forward." The board also expressed gratitude toward Geoff Klass for his steadfast guidance in navigating the company through essential fundraising and product development phases.

Kurdziel’s educational background includes a Bachelor of Science in Finance and Management from Canisius University, complemented by a Master of Business Administration in Finance from the University at Buffalo. His entrepreneurial spirit is evident in his role as the founder of NeuraVision Partners, which provides strategic support to early-stage medical device companies.

Looking Ahead

As Gary Kurdziel steps into his new role, the focus will be on making significant strides within the company’s innovative product landscapes, particularly in enhancing patient care for those affected by neurological disorders.

The leadership transition highlights a continuity strategy designed to support employees and reassure investors of the company’s steadfast dedication to developing groundbreaking technologies aimed at continuous brain injury detection and monitoring. With a clear vision and a robust strategic plan in place, Sense Neuro Diagnostics is on track to navigate the complexities of the medical device industry while enhancing patient outcomes globally.

For further inquiries, please contact Paul Gaitan, Chief Financial Officer at Sense Neuro Diagnostics.

About Sense Neuro Diagnostics

Sense Neuro Diagnostics is dedicated to developing innovative technologies designed for continuous, real-time brain injury detection and monitoring. Through proprietary noninvasive techniques, the company seeks to improve health outcomes for patients suffering from traumatic brain injuries, strokes, and other neurological conditions.